What Novoprotein does

Novoprotein (Suzhou Novoprotein Technology Co., Ltd.) is a privately-held Chinese biotechnology company founded in 2009 that develops recombinant proteins, antibodies, and RNA synthesis tools for the life sciences industry. The company operates four expression platforms (E.coli, Mammalian, Yeast, Insect) and offers a catalog of recombinant proteins, cytokines, target proteins, GMP-grade cytokines and antibodies, organoid-validated growth factors, mRNA synthesis enzymes, gene therapy products, and virus-related reagents. Its proprietary technology includes the FlashPrep® high-throughput RNA synthesis and detection platform supporting IVT mRNA, circRNA, and SaRNA production, as well as clinical-grade gene editors AaCas12bMax and enCas12Ultra developed in partnership with Vitalgen and Lumiere Therapeutic respectively. The company is headquartered in Suzhou with additional offices in Shanghai and Heze, and operates through a global network of authorized distributors.

The company's business model combines one-time catalog product sales with professional CRO services. Catalog products include recombinant proteins, cytokines, target proteins, molecular biology enzymes, antibodies, and virus-related products sold to research and biomanufacturing customers. CRO services span protein expression and purification, antibody discovery (phage display and hybridoma), antibody engineering (humanization, affinity maturation, bispecific/multispecific, nanobody), IVT mRNA/circRNA/SaRNA production, and CMC Development with GMP Manufacturing. The company goes to market through direct enterprise sales (segmented email funnel for product, service, and support inquiries), conference participation at major industry events (ASGCT, AACR, PEGS, ISSCR, mRNA-Based Therapeutics), authorized distributors across USA, UK, Germany, France, Japan, Singapore, and Canada, and an e-commerce storefront for catalog orders. Primary customer segments are cell and gene therapy companies and antibody drug developers, with life science researchers and molecular diagnostics companies as secondary segments.

Strategic posture centers on positioning as a one-stop CRO services platform for cell and gene therapy raw materials, supported by GMP-compliant manufacturing capabilities, quality management system certifications across all three facilities, and clinical-grade gene editing tools. The company was awarded Asia Pacific CGT Industry Star Raw Material Provider of the Year in both 2023 and 2024, and an FDA IND approval milestone was achieved for a partner's AaCas12bMax-based TIL therapy in 2025. Revenue is not publicly disclosed and no venture capital funding rounds have been reported, indicating organic growth primarily funded by operations.

Name

Novoprotein

Legal name

Suzhou Novoprotein Technology Co., Ltd.

Website

https://novoprotein.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Novoprotein is a Suzhou, China-based biotech company founded in 2009 that supplies recombinant proteins, cytokines, GMP-grade reagents, and CRO services for antibody discovery, RNA synthesis, and cell and gene therapy development worldwide.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Reagents and CRO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

akta.pro secondary industries

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Recombinant proteins
• Cytokines and antibodies
• MRNA synthesis services
• Gene therapy reagents
• CRO services

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Catalog Products: Sale of recombinant proteins, cytokines, target proteins, molecular biology enzymes, antibodies, and virus-related products for research and manufacturing purposes
2. CRO Services: Custom research services including protein expression and purification, antibody development, mRNA synthesis, and related technical services

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Novoprotein manufactures and sells recombinant proteins, cytokines, antibodies, target proteins, and molecular biology enzymes (including GMP-grade materials) for cell therapy, gene therapy, mRNA vaccine, and antibody drug development. The company also provides CRO services covering protein expression and purification, antibody discovery and engineering, and IVT mRNA/circRNA/SaRNA synthesis (including the proprietary FlashPrep platform) through its Suzhou, Shanghai, and Heze facilities.

Product overview

Novoprotein is a life sciences company specializing in recombinant proteins, antibodies, and RNA synthesis solutions. The company operates as a unified platform offering both products and CRO (Contract Research Organization) services. The product portfolio includes mRNA Vaccine & Drug Enzymes, Gene and Cell Therapy products (including Cas12b editors like AaCas12bMax and enCas12Ultra), Cytokines, Target Proteins, Biosimilar Reference Antibodies, Molecular Research enzymes, Molecular Diagnostics reagents, and Virus-related products. The services encompass protein expression and purification (E.coli, Mammalian, Yeast, Insect systems), antibody development (phage display, hybridoma), antibody optimization (humanization, affinity maturation), antibody production (recombinant IgG, bispecific/multispecific, nanobodies), and IVT mRNA/circRNA/SaRNA production services including the FlashPrep® high-throughput platform. Featured products include Organoid-Validated Growth Factors and Cytokines, the circRNA Synthesis Solution platform, and GMP-Grade Cytokines/Antibodies for cell therapy applications.

Differentiator

Problem solved

Functional benefit

Brands

• NovoNectin®: GMP Grade cytokine product line
• Tscm Expander®
• FlashPrep®

Products and services

• Recombinant Cytokines and Growth Factors Recombinant cytokines, growth factors, and related proteins for cell culture, organoid and 3D culture systems, research, and therapeutic applications, including GMP-grade options for cell therapy. Intended for life science researchers and biopharmaceutical manufacturers.
• Target Proteins High-quality target proteins to accelerate antibody drug development processes with reliability and consistency. Intended for pharmaceutical and biotech companies developing antibody-based therapeutics.
• GMP-Grade Cytokines and Antibodies Good Manufacturing Practice (GMP) grade cytokines and antibodies designed for cell therapy applications, meeting regulatory requirements. Includes the NovoNectin® GMP-grade cytokine brand. Intended for cell and gene therapy manufacturers.
• mRNA Vaccine and Drug Enzymes Enzymes and proteins (including capping enzymes and polymerases) essential for mRNA vaccine and drug development. Intended for mRNA therapeutics manufacturers and developers.
• AaCas12bMax Gene Editor Clinical-grade Cas12b gene editor with zero off-target effects, developed for cell and gene therapy applications in partnership with Vitalgen. Intended for gene therapy and cell therapy developers.
• enCas12Ultra Gene Editor Enhanced Cas12 Ultra nuclease for cell and gene therapy applications, developed in partnership with Lumiere Therapeutic. Intended for gene therapy and cell therapy developers.
• Biosimilar Reference Antibodies Biosimilar reference antibodies for research and development comparison studies. Intended for biosimilar developers and antibody drug developers.
• Molecular Diagnostics Reagents and Virus-Related Products Raw materials and reagents for molecular diagnostic and immunodiagnostic applications, including viral antigens and antibodies for RSV, HSV, MPXV, and other pathogens. Intended for diagnostic assay manufacturers.
• Protein Expression and Purification Services Recombinant protein expression and purification services using E.coli, Mammalian (for complex proteins requiring proper folding and post-translational modifications), Yeast, and Insect cell expression systems, as well as VLP protein production and renaturation of inclusion body proteins. Intended for biopharmaceutical researchers and manufacturers.
• Antibody Development and Production Services Comprehensive antibody CRO services including phage display-based antibody discovery, hybridoma-based antibody discovery, hybridoma antibody gene sequencing, activity detection (SPR/BLI), cell line detection and customization, antibody humanization, antibody affinity maturation, recombinant full-length IgG production, bispecific/multispecific antibody and nanobody production, rabbit polyclonal antibody production, and stable cell line construction. Intended for antibody drug developers.
• IVT mRNA/circRNA/SaRNA Production Services Full suite of in vitro transcription services including RNA sequence design and optimization, plasmid construction and production, linear mRNA synthesis, circular RNA synthesis, self-amplifying RNA synthesis, RNA-LNP encapsulation, and full-process QC services. Includes the proprietary FlashPrep® high-throughput RNA synthesis and detection platform. Intended for mRNA therapeutics developers and vaccine manufacturers.
• CMC Development and GMP Manufacturing Services Chemistry, Manufacturing, and Controls (CMC) development along with GMP manufacturing services for industrial production, including industrial strain and process development, multi-process optimization, and scalable solutions for industrial production. Intended for biopharmaceutical manufacturers.

Quantifiable outcome

• FDA IND approval milestone achieved for AaCas12bMax-based next-generation gene-edited TIL therapy

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• VitalgencoreStrategic or Co-development Partner · 1 January 2024Strategic collaboration to promote commercial application of AaCas12bMax, a clinical-grade gene editor with '0 off-target' characteristics. AaCas12bMax has achieved FDA IND approval milestone for next-generation gene-edited TIL therapy.
• Lumiere TherapeuticcoreStrategic or Co-development Partner · 1 January 2024Strategic cooperation to advance commercial application of enCas12Ultra in cell and gene therapy, leveraging Novoprotein's protein technology capabilities.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Sino Biological: Sino Biological is a China-headquartered recombinant protein manufacturer with a directly overlapping catalog of cytokines, antibodies, and target proteins for research and biopharma customers. Both companies serve the same CGT and antibody drug developer segments with comparable E.coli, mammalian, and yeast expression capabilities.
• ACROBiosystems: ACROBiosystems is a direct competitor offering recombinant proteins, virus-related reagents, and magnetic beads for biologics development, with overlapping product categories in target proteins, biosimilar antibodies, and CGT raw materials. Both companies target the same antibody drug developer and cell therapy customer base.
• GenScript: GenScript offers protein expression and purification services, antibody development (phage display and hybridoma), and gene synthesis through its ProBio biologics CDMO. The service portfolio and customer segments overlap directly with Novoprotein's CRO offerings across protein and antibody workflows.
• TriLink BioTechnologies: TriLink specializes in mRNA synthesis, modified nucleotides, and LNP encapsulation services for mRNA vaccine and therapeutic developers. Both companies offer plasmid construction, IVT mRNA production, and RNA-LNP encapsulation as core services to overlapping mRNA therapeutic customers.
• Aldevron: Aldevron (now part of Danaher) manufactures plasmid DNA, mRNA, and recombinant proteins for cell and gene therapy developers. It competes directly with Novoprotei's nucleic acid manufacturing services and CGT raw materials, serving overlapping gene therapy and mRNA therapeutic customers.

Broad incumbents

• Bio-Techne: Bio-Techne (R&D Systems brand) is a large incumbent offering recombinant proteins, antibodies, and GMP-grade reagents for research and cell therapy applications. It competes with Novoprotein across the catalog recombinant protein category but operates at substantially greater scale with a much broader life sciences portfolio.
• Cytiva: Cytiva (Danaher) provides bioprocessing equipment, resins, and biopharma manufacturing services to the same CGT and biologics customers. Its nucleic acid manufacturing services and cell therapy workflow solutions overlap with Novoprotein's GMP manufacturing and mRNA service offerings.
• WuXi Biologics: WuXi Biologics is a large China-based biologics CDMO offering CMC development, GMP manufacturing, and protein expression services. It competes with Novoprotein's CRO and GMP manufacturing services but operates at significantly larger scale with a global manufacturing footprint.
• Abcam: Abcam (now part of Danaher) is a major supplier of antibodies and protein research reagents with overlapping catalog products including recombinant antibodies and tagged proteins. Both companies serve academic and industrial life science researchers requiring validated antibodies and proteins.
• Thermo Fisher Scientific: Thermo Fisher Scientific offers a broad portfolio of life sciences reagents, proteins, and biopharma services through its Biosciences and Pharma Services segments. It competes with Novoprotein across multiple product categories including proteins, antibodies, and cell therapy manufacturing services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/novoprotein

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novoprotein